<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322049</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR 824</org_study_id>
    <secondary_id>HSRRB Log A-10064</secondary_id>
    <secondary_id>GSK CPMS7663310/001</secondary_id>
    <secondary_id>DEN-001</secondary_id>
    <nct_id>NCT00322049</nct_id>
  </id_info>
  <brief_title>A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants</brief_title>
  <official_title>A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main target populations for the tetravalent live attenuated dengue virus vaccine are
      indigenous populations, especially infants less than 2 years old, residing in areas of the
      world endemic for dengue and at risk of developing dengue hemorrhagic fever (DHF). The
      presence of maternal dengue antibody during the first year of life makes it unlikely that a
      vaccine given during that time will have long-term efficacy, as the vaccine virus would
      likely be neutralized prior to necessary replication. Children older than 18 months may have
      preexisting flavivirus antibody. Therefore, vaccination of infants living in Thailand early
      in the second year of life (between the ages of 12 and 18 months) seems most beneficial. The
      aim of this trial is to evaluate the safety and immunogenicity of a two-dose schedule of a
      tetravalent live attenuated dengue vaccine in flavivirus antibody naïve infants beginning at
      12-15 months of age.

        -  To assess the kinetics of dengue neutralizing antibodies to each dengue virus serotype
           one and four years following dose 2 of dengue/control vaccination in the setting of
           potential wild-type dengue virus exposure.

        -  To assess the immunogenicity, the safety and reactogenicity of a booster dose of dengue
           vaccine administered at Year 3 following primary vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a Phase I/II, randomized, observer-blind, controlled trial. Thirty-four
           flavivirus naïve infants will be randomized to the vaccine group and 17 infants to the
           control group.

        -  Infants receive dengue vaccine at study months 0 and 6 or control vaccine (Varicella
           vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study
           month 6). Both are licensed for use in Thailand.

        -  All infants subsequently receive an inactivated JE vaccine approximately one and 1.5
           months following dengue vaccine dose 2.

        -  Infants are monitored daily for 21 days following each dengue or control vaccination and
           7 days after each JE vaccination for solicited adverse events. Unsolicited events will
           be recorded up to 31 days (days 0-30) after dengue/control vaccinations and each day
           after dose 1 of JE vaccine until the concluding study visit.

        -  Study duration (excluding screening) is approximately 8.5 months for each subject.

        -  Each enrollee is followed a four year period following dose 2 of dengue/control
           vaccination to assess for dengue-related hospitalizations and dengue antibody kinetics.

        -  Investigators will administer a 3rd dose of tetravalent dengue vaccine to all subjects
           who received 2 doses of dengue vaccine (0 and 6 months) during the primary phase of the
           study. The 3rd dose will be administered 3 years following the primary vaccination
           series. Peripheral blood mononuclear cells (PBMCs) and sera will be collected at the
           time of dose 3, and twice again at one month and one year following dose 3 from dengue
           group subjects.

      Investigators will address the following questions:

        1. Is a 3rd dose of live virus tetravalent dengue vaccine safe in Thai toddlers/children?

        2. Is a 3rd dose of live virus tetravalent dengue vaccine required in toddlers/children to
           induce optimal immune (neutralizing antibody, cellular mediated immunity) responses?

        3. Is there evidence of T and B cell memory following a primary dengue vaccination series
           (dose 1 and 2)?

        4. How does a 3rd dose of live virus tetravalent dengue vaccine impact B and T cell memory?
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine.</measure>
    <time_frame>21-day follow-up period after Dose 1</time_frame>
    <description>Local and general solicited reactogenicity using diary cards for 21 days (days 0-20) after the first dose of dengue/control vaccine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) for N Antibody to All Four Serotypes and Japanese Encephalitis (JE) Vaccine</measure>
    <time_frame>30 days post Dose 2</time_frame>
    <description>Assess the immunogenicity of the dengue vaccine in terms of GMTs 30 days post-Dose 2 of dengue vaccine for all four serotypes (DEN-1, 2, 3, 4 and JE (Japanese encephalitis)). Analysis of immunogenicity was performed on the ATP cohort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dose 2</measure>
    <time_frame>month 7 after dose 2</time_frame>
    <description>Seronegative for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2.
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dengue Dose 2 (and 2 Doses of JE</measure>
    <time_frame>month 8.5</time_frame>
    <description>Seropositivity for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2 (and 2 doses of JE).
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>JE Vaccine Response</measure>
    <time_frame>Pre-vaccination, 1, 6, 7 and 8.5 months after two doses of dengue vaccine</time_frame>
    <description>Seropositivity rates and GMTs for N lg to JEV antibodies. Pre= Pre vaccination, blood sampling prior to the first vaccine dose; PI(M1)= Post 1, month 1, blood sampling one month after dose 1 at study month 1; PI(M6)= Post 1, month 6, blood sampling 6 months after dose 1 at study month 6; PII(M7)= Post II, month 7, blood sampling one month after dose 2 at study month 7; PIV(M8.5)= Post IV, month 8.5, blood sampling after 2 doses of dengue/control and 2 doses of JE vaccines at study month 8.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Dengue Specific Symptoms</measure>
    <time_frame>30-day follow-up period after dose 1 and 2</time_frame>
    <description>Percentage of subjects showing incidence of dengue specific symptoms during the 30-day follow-up period after vaccinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Dengue Viremia 10 Days Post Booster Dose</measure>
    <time_frame>10 days after post dose 1 and 2</time_frame>
    <description>Percentage of subjects with a dengue viremia 10 days after each dose of vaccine.
RT PCR = Reverse-transcriptase polymerase chain reaction Nested PCR - Nested polymerase chain reaction
Per protocol, all participants receiving a Dengue Vaccine were combined for Dengue Viremia assessment via RT-PCR and Nested PCR</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;
DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Control vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetravalent live attenuated dengue vaccine</intervention_name>
    <description>DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.
Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.
A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit).</description>
    <arm_group_label>Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )</arm_group_label>
    <arm_group_label>Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine</intervention_name>
    <description>Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.</description>
    <arm_group_label>Cohort B: Control vaccines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female infants between 12 and 15 months (12 and &lt;16 months) of age at the
             time of the first dengue vaccination

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study. As a marker of nutritional status, an
             infant's weight to height ratio will be above the 5th percentile compared to the
             standards for same sex and age children cared for at Phramongkutklao Hospital,
             Bangkok, Thailand

          -  Written informed consent obtained from the parent of the subject.

        Amendment 8 Inclusion Criteria:

          -  Completed the Dengue-001 study having previously received 2 doses of experimental
             dengue vaccine according to protocol.

          -  Written informed consent obtained from the parent or guardian of the subject.
             (obtained in amendment 5)

          -  Written informed consent obtained from the parent or guardian of the subject who
             agrees to their child's participation to receive a dengue booster dose and booster
             follow-up.

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the
             protocol-specified vaccines within 30 days preceding the administration of the first
             dose of dengue/control vaccine or planned use during the study period

          -  Administration of a registered vaccine within 30 days preceding the first study
             vaccination or planned administration within 30 days prior to, or 30 days after any
             protocol-specified vaccine administration

          -  MMR vaccination given within 60 days prior to the first dose of dengue/control vaccine
             (added bullet point, or planned administration within 60 days prior to, or 30 days
             after any protocol-specified vaccine administration

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs during the study period. (For corticosteroids, this will mean
             prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition

          -  Any clinically significant history, including any seizures or other serious medical
             condition as determined by the investigator

          -  A first order family member (parent or sibling) with a history of chronic headaches

          -  A first order family member (parent or sibling) with a history of a congenital or
             hereditary immunodeficiency

          -  Abnormal clinical laboratory screening test results (based on normal values set by the
             laboratory) that are deemed clinically significant by study investigators and/or the
             Medical Monitor

          -  The presence of HBsAg or antibodies against HIV or HCV at screening

          -  Pre-existing antibody to dengue 1-4 virus serotypes or Japanese encephalitis virus
             (JEV) by HAI or PRNT50 at screening

          -  Previous vaccination against yellow fever virus, JEV, tick-borne encephalitis virus
             (TBE), varicella virus or booster dose of Hib in the second year of life

          -  History of varicella disease or invasive Haemophilus Influenzae B disease

          -  Acute disease at time of enrollment (Acute illness is defined as the presence of a
             moderate or severe illness with or without fever). All vaccines can be administered to
             persons with a minor illness such as diarrhea or mild upper respiratory infection with
             or without low-grade febrile illness, i.e., axillary temperature &lt;37.5°C (&lt;99.5°F).

          -  Administration of immunoglobulins and/or blood products since birth or planned
             administration during the study period

          -  Known allergic or idiosyncratic reaction to neomycin or related antibiotics (including
             streptomycin, gentamicin, amikacin, , tobramycin, kanamycin and bacitracin)

          -  Allergy to dogs or monkeys or hypersensitivity to proteins of rodent or neural origin

          -  Allergy to gelatin or hypersensitivity to thimerosal

          -  Infant whose parent has no easy access to a fixed or mobile telephone

          -  Parental illiteracy

          -  Plans to leave Bangkok during the first 8.5 months after initial vaccination or
             definite plans to move from Bangkok during the 5 years following first dose
             dengue/control vaccination.

        Amendment 8 Exclusion Criteria:

        -Any subject with confirmed dengue hemorrhagic fever during the 2 to 3 year period before
        booster dose administration will not be eligible for enrollment for the booster.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>15 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert V. Gibbons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.S. Army Medical Component Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veerachai Watanaveeradej, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Disease Department of Pediatrics Phramongkutklao Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USAMC-AFRIMS/Department of Pediatrics, Pharamongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2006</study_first_submitted>
  <study_first_submitted_qc>May 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2017</results_first_posted>
  <disposition_first_submitted>February 16, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 17, 2017</disposition_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue, Vaccine, Thailand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>51 infants enrolled and vaccinated for safety cohort, all received dose 1 and 50 completed the study. 49 vaccinated for ATP immunogenicity cohort.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
          <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="P2">
          <title>Cohort B - Full Dose Dengue Vaccine</title>
          <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="P3">
          <title>Cohort C - Full Dose Dengue Vaccine</title>
          <description>Full-dose dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="P4">
          <title>Control Group - Hib Vaccine</title>
          <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Moved out of area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Infected with Dengue during study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
          <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="B2">
          <title>Cohort B - Full Dose Dengue Vaccine</title>
          <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="B3">
          <title>Cohort C - Full Dose Dengue Vaccine</title>
          <description>Full-dose dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
        </group>
        <group group_id="B4">
          <title>Control Group - Hib Vaccine</title>
          <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="17"/>
            <count group_id="B5" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.0" spread="0.00"/>
                    <measurement group_id="B2" value="13.3" spread="0.82"/>
                    <measurement group_id="B3" value="13.6" spread="0.88"/>
                    <measurement group_id="B4" value="13.6" spread="0.79"/>
                    <measurement group_id="B5" value="13.6" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Southeast Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine.</title>
        <description>Local and general solicited reactogenicity using diary cards for 21 days (days 0-20) after the first dose of dengue/control vaccine</description>
        <time_frame>21-day follow-up period after Dose 1</time_frame>
        <population>Format of results is consistent with how data was presented in the Final Clinical Study Report. Combining of cohorts B and C was due to both cohorts being full dose</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group - Hib Vaccine</title>
            <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
        </group_list>
        <measure>
          <title>Reactogenicity in Terms of Solicited Symptoms After Dose 1 of the Dengue Vaccine vs. Control Vaccine.</title>
          <description>Local and general solicited reactogenicity using diary cards for 21 days (days 0-20) after the first dose of dengue/control vaccine</description>
          <population>Format of results is consistent with how data was presented in the Final Clinical Study Report. Combining of cohorts B and C was due to both cohorts being full dose</population>
          <units>specified events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 : Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 : Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 : Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 : Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 : Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 : Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose : Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose : Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose : Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / subject : Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / subject : Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / subject : Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Decreased activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Fever (axillary celsius)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall / dose - Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) for N Antibody to All Four Serotypes and Japanese Encephalitis (JE) Vaccine</title>
        <description>Assess the immunogenicity of the dengue vaccine in terms of GMTs 30 days post-Dose 2 of dengue vaccine for all four serotypes (DEN-1, 2, 3, 4 and JE (Japanese encephalitis)). Analysis of immunogenicity was performed on the ATP cohort.</description>
        <time_frame>30 days post Dose 2</time_frame>
        <population>GMT calculated on all subjects. Dil = Dilution; P1(M1) = blood sampling on month after dose 1, at study month 1; PII(M7) = blood sampling one month after dose 2, at study month 7; PII(M8.5) = blood sampling 2 1/2 months after dose 2, at study month 8.5. Combining of cohorts B and C was due to both cohorts being full dose</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group - Hib Vaccine</title>
            <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) for N Antibody to All Four Serotypes and Japanese Encephalitis (JE) Vaccine</title>
          <description>Assess the immunogenicity of the dengue vaccine in terms of GMTs 30 days post-Dose 2 of dengue vaccine for all four serotypes (DEN-1, 2, 3, 4 and JE (Japanese encephalitis)). Analysis of immunogenicity was performed on the ATP cohort.</description>
          <population>GMT calculated on all subjects. Dil = Dilution; P1(M1) = blood sampling on month after dose 1, at study month 1; PII(M7) = blood sampling one month after dose 2, at study month 7; PII(M8.5) = blood sampling 2 1/2 months after dose 2, at study month 8.5. Combining of cohorts B and C was due to both cohorts being full dose</population>
          <units>titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DEN-1 GMT - PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-1 GMT - PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="6.1" lower_limit="3.3" upper_limit="11.4"/>
                    <measurement group_id="O3" value="20.7" lower_limit="11.4" upper_limit="37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-2 GMT - PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="8.8" lower_limit="1.4" upper_limit="54.4"/>
                    <measurement group_id="O3" value="13.7" lower_limit="7.7" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-2 GMT - PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="173.6" lower_limit="50.1" upper_limit="601.5"/>
                    <measurement group_id="O3" value="239.6" lower_limit="163.6" upper_limit="351.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-3 GMT - PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-3 GMT PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="29.2" lower_limit="18.6" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-4 GMT PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="15.7" lower_limit="0.4" upper_limit="600.1"/>
                    <measurement group_id="O3" value="22.5" lower_limit="10.0" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DEN-4 GMT PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="31.9" lower_limit="2.5" upper_limit="408.2"/>
                    <measurement group_id="O3" value="52.5" lower_limit="29.0" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE Vaccine GMT PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="5.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE Vaccine GMT PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="8.3" lower_limit="5.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JE Vaccine GMT PII(M8.5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="7.4" upper_limit="38.1"/>
                    <measurement group_id="O2" value="19.3" lower_limit="7.0" upper_limit="52.9"/>
                    <measurement group_id="O3" value="12.9" lower_limit="6.7" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dose 2</title>
        <description>Seronegative for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2.
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
        <time_frame>month 7 after dose 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - Full Dose Dengue Vaccine</title>
            <description>Full-dose dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O4">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full dose dengue vaccine at study months 0 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dose 2</title>
          <description>Seronegative for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2.
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
          <units>% of responders</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N lg to DEN-1 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O3" value="40.0" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O4" value="55.2" lower_limit="35.7" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="39.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="87.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="80.0" lower_limit="56.3" upper_limit="94.3"/>
                    <measurement group_id="O4" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="94.7" lower_limit="74.0" upper_limit="99.9"/>
                    <measurement group_id="O4" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dengue Dose 2 (and 2 Doses of JE</title>
        <description>Seropositivity for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2 (and 2 doses of JE).
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
        <time_frame>month 8.5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O2">
            <title>Cohort B - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohort C - Full Dose Dengue Vaccine</title>
            <description>Full-dose dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O4">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full dose dengue vaccine at study months 0 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Seronegative Neutralizing (N) Antibody Titers to Each DEN Serotype After Dengue Dose 2 (and 2 Doses of JE</title>
          <description>Seropositivity for N antibody against DEN 1, 2, 3 and 4 antibody after dengue dose 2 (and 2 doses of JE).
Seronegative (antibody titer &lt;10 1/Dil for N lg to DEN-1, N lg to DEN-2, N lg to DEN-3, N lg) prior to vaccination.</description>
          <units>% of responders</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N lg to DEN-1 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O2" value="55.6" lower_limit="21.2" upper_limit="86.3"/>
                    <measurement group_id="O3" value="35.0" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O4" value="41.4" lower_limit="23.5" upper_limit="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-2 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="39.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="82.4" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="87.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-3 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O2" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                    <measurement group_id="O3" value="60.0" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O4" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg to DEN-4 (Dil)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O3" value="60.0" lower_limit="36.1" upper_limit="80.9"/>
                    <measurement group_id="O4" value="69.0" lower_limit="49.2" upper_limit="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>JE Vaccine Response</title>
        <description>Seropositivity rates and GMTs for N lg to JEV antibodies. Pre= Pre vaccination, blood sampling prior to the first vaccine dose; PI(M1)= Post 1, month 1, blood sampling one month after dose 1 at study month 1; PI(M6)= Post 1, month 6, blood sampling 6 months after dose 1 at study month 6; PII(M7)= Post II, month 7, blood sampling one month after dose 2 at study month 7; PIV(M8.5)= Post IV, month 8.5, blood sampling after 2 doses of dengue/control and 2 doses of JE vaccines at study month 8.5</description>
        <time_frame>Pre-vaccination, 1, 6, 7 and 8.5 months after two doses of dengue vaccine</time_frame>
        <population>Combining of cohorts B and C was due to both cohorts being full dose</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group - Hib Vaccine</title>
            <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
        </group_list>
        <measure>
          <title>JE Vaccine Response</title>
          <description>Seropositivity rates and GMTs for N lg to JEV antibodies. Pre= Pre vaccination, blood sampling prior to the first vaccine dose; PI(M1)= Post 1, month 1, blood sampling one month after dose 1 at study month 1; PI(M6)= Post 1, month 6, blood sampling 6 months after dose 1 at study month 6; PII(M7)= Post II, month 7, blood sampling one month after dose 2 at study month 7; PIV(M8.5)= Post IV, month 8.5, blood sampling after 2 doses of dengue/control and 2 doses of JE vaccines at study month 8.5</description>
          <population>Combining of cohorts B and C was due to both cohorts being full dose</population>
          <units>% of subjects with titer within range</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N lg against JEV &gt;10 1/Dil - PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - PRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg against JEV &gt;10 1/Dil - PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O3" value="13.8" lower_limit="3.9" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - PI(M1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="5.0" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg against JEV &gt;10 1/Dil - PI(M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="0.2" upper_limit="30.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - PI(M6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.7" upper_limit="5.9"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg against JEV &gt;10 1/Dil - PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="20.6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O3" value="17.9" lower_limit="6.1" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - PII(M7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="8.3" lower_limit="5.1" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N lg against JEV &gt;10 1/Dil - PIV(M8.5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="29.9" upper_limit="80.2"/>
                    <measurement group_id="O2" value="100" lower_limit="39.8" upper_limit="100"/>
                    <measurement group_id="O3" value="32.1" lower_limit="15.9" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT - PIV(M8.5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="7.4" upper_limit="38.1"/>
                    <measurement group_id="O2" value="19.3" lower_limit="7.0" upper_limit="52.9"/>
                    <measurement group_id="O3" value="12.9" lower_limit="6.7" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Dengue Specific Symptoms</title>
        <description>Percentage of subjects showing incidence of dengue specific symptoms during the 30-day follow-up period after vaccinations</description>
        <time_frame>30-day follow-up period after dose 1 and 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cohort A - 1/10th Dose Dengue Vaccine</title>
            <description>1/10th full dose at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O3">
            <title>Cohort B - Full Dose Dengue Vaccine</title>
            <description>Full-dose of dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O4">
            <title>Cohort C - Full Dose Dengue Vaccine</title>
            <description>Full-dose dengue vaccine at study months 0 and 6 or control vaccines (varicells vaccine at study month 0 and Hib vaccine at study month 6)</description>
          </group>
          <group group_id="O5">
            <title>Cohorts B &amp; C - Full Dose Dengue Vaccine</title>
            <description>Full dose dengue vaccine at study months 0 and 6</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Dengue Specific Symptoms</title>
          <description>Percentage of subjects showing incidence of dengue specific symptoms during the 30-day follow-up period after vaccinations</description>
          <units>% of subjects with specified symptoms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 - Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.15" upper_limit="28.69"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="30.0" lower_limit="6.67" upper_limit="65.25"/>
                    <measurement group_id="O4" value="15.0" lower_limit="3.21" upper_limit="37.89"/>
                    <measurement group_id="O5" value="20.0" lower_limit="7.71" upper_limit="38.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Conjunctival hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Conjunctival injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Mucosal hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="25.0" lower_limit="0.63" upper_limit="80.59"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="44.04" upper_limit="89.69"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.76" upper_limit="93.24"/>
                    <measurement group_id="O3" value="80.0" lower_limit="44.39" upper_limit="97.48"/>
                    <measurement group_id="O4" value="50.0" lower_limit="27.20" upper_limit="72.80"/>
                    <measurement group_id="O5" value="60.0" lower_limit="40.60" upper_limit="77.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Hepatomegaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 - Splenomegaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="1.46" upper_limit="36.44"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="10.0" lower_limit="0.25" upper_limit="44.50"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.13" upper_limit="24.87"/>
                    <measurement group_id="O5" value="6.7" lower_limit="0.82" upper_limit="22.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Conjunctival hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.54"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Conjunctival injecgtion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="0.15" upper_limit="28.69"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="15.0" lower_limit="3.21" upper_limit="37.89"/>
                    <measurement group_id="O5" value="10.0" lower_limit="2.11" upper_limit="26.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Mucosal hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Lymphadenopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="32.92" upper_limit="81.56"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.41" upper_limit="99.37"/>
                    <measurement group_id="O3" value="60.0" lower_limit="26.24" upper_limit="87.84"/>
                    <measurement group_id="O4" value="25.0" lower_limit="8.66" upper_limit="49.10"/>
                    <measurement group_id="O5" value="36.7" lower_limit="19.93" upper_limit="56.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Hepatomegaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 - Spenomegaly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="19.51"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="60.24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="30.85"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="16.84"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.00" upper_limit="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Dengue Viremia 10 Days Post Booster Dose</title>
        <description>Percentage of subjects with a dengue viremia 10 days after each dose of vaccine.
RT PCR = Reverse-transcriptase polymerase chain reaction Nested PCR - Nested polymerase chain reaction
Per protocol, all participants receiving a Dengue Vaccine were combined for Dengue Viremia assessment via RT-PCR and Nested PCR</description>
        <time_frame>10 days after post dose 1 and 2</time_frame>
        <population>All participants with evaluable results are reported via RT-PCR and Nested PCR analysis. Scheduled phlebotomy and unscheduled phlebotomy when a subject was ill during the study revealed dengue viremia by RT-/nested PCR, for seven subjects (2 in cohort B and 5 in cohort C).</population>
        <group_list>
          <group group_id="O1">
            <title>Subject With Viremia Measured by: RT-PCR</title>
            <description>Scheduled phlebotomy and unscheduled phlebotomy when a subject was ill during the study revealed dengue viremia</description>
          </group>
          <group group_id="O2">
            <title>Subject With Viremia Measured by: Nested PCR</title>
            <description>Scheduled phlebotomy and unscheduled phlebotomy when a subject was ill during the study revealed dengue viremia</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With a Dengue Viremia 10 Days Post Booster Dose</title>
          <description>Percentage of subjects with a dengue viremia 10 days after each dose of vaccine.
RT PCR = Reverse-transcriptase polymerase chain reaction Nested PCR - Nested polymerase chain reaction
Per protocol, all participants receiving a Dengue Vaccine were combined for Dengue Viremia assessment via RT-PCR and Nested PCR</description>
          <population>All participants with evaluable results are reported via RT-PCR and Nested PCR analysis. Scheduled phlebotomy and unscheduled phlebotomy when a subject was ill during the study revealed dengue viremia by RT-/nested PCR, for seven subjects (2 in cohort B and 5 in cohort C).</population>
          <units>% of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 days post dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 days post dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8.5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A: Dengue Vaccine- 1/10 Dose (T-DEN F17 )</title>
          <description>Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;</description>
        </group>
        <group group_id="E2">
          <title>Cohort B: Full Dose (T-DEN F17 )</title>
          <description>Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
        </group>
        <group group_id="E3">
          <title>Cohort C: Dengue Vaccine - Full Dose (T-DEN F17 )</title>
          <description>Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years</description>
        </group>
        <group group_id="E4">
          <title>Control Group</title>
          <description>Hemophilus influenza type b (Hib) vaccine and varicella vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastroenteritis with dehydration</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Acute gastroenteritis with febrile seizure</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Viral gastritis with dehydration/vomiting, fever</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture left forearm</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Dose 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Dose 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Dose 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Dose 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness</sub_title>
                <description>Dose 1</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Dose 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wipa Chawachalasai</name_or_title>
      <organization>U.S. Army Medical Component Armed Forces Research Institute of Medical Services</organization>
      <phone>662-696-2700 ext 4351</phone>
      <email>wipac@afrims.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

